


First phase III trial to personalize the adjuvant window, demonstrating an overall survival (OS) benefit in MIBC




MRD guided treatment more than doubled disease-free survival (DFS) and delivered a 41% OS improvement in Signatera™-positive MIBC patients treated with atezolizumab

DFS in Signatera™-positive patients



OS in Signatera™-positive patients




- DFS and OS benefit was consistent across subgroups, including nodal disease, higher stage, and prior NAC
- Benefit observed whether patients were Signatera™-positive at baseline or converted during surveillance, underscoring the value of serial testing


Serially Signatera™-negative patients had excellent survival outcomes without adjuvant therapy

Supporting a personalized, MRD-guided approach that safely spares patients unnecessary treatment and toxicity

DFS in Signatera™-negative patients




OS in Signatera™-negative patients



IMvigor011 establishes Signatera™ as the first ctDNA test validated in a randomized phase III trial to guide adjuvant therapy in MIBC

Changing the paradigm in muscle invasive bladder cancer: Treat on molecular recurrence (TOMR)

IMvigor011 study schema



Testing cadence: Serial Signatera™ MRD testing every 6 weeks for 9 months to detect molecular recurrence

Practice-changing biomarker with broad applicability

Beyond the primary results, IMvigor011 provides evidence supporting the clinical utility of Signatera™ across patient groups and treatment settings.

- **Consistency across patient groups** – treatment benefit was observed across nodal status, tumor stage, and prior NAC—enhancing risk stratification beyond surgical pathology.
- **Power of serial monitoring** – patients who became Signatera™-positive during the follow-up derived the same DFS and OS benefit as those positive at baseline—proving the value of continued Signatera™ surveillance.
- **A new paradigm independent of the adjuvant regimen** – IMvigor011 is the first randomized phase 3 trial to demonstrate an OS benefit with a Signatera™-positive guided approach—validating biomarker-guided care as the new standard of care in MIBC.

Learn how Signatera™ guides therapy decisions, predicts treatment benefit, and detects recurrence earlier in MIBC



Powles T., et al., IMvigor011: a Phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer as presented at 2025 European Society of Medical Oncology (ESMO) Annual Meeting

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com

Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.
© 2025 Natera, Inc. All Rights Reserved. SGN_OS_IMvigor011_20251022_NAT-8022790